Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00307736 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00307736: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00307736 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00307736, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating(Phase II portion) patients with locally advanced rectal cancer.
Interventions
- DRUG 5-fluorouracil
- DRUG bevacizumab
- DRUG erlotinib
- PROCEDURE External beam radiation therapy (EBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00307736
The ClinicalTrials.gov registry entry for NCT00307736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 5-fluorouracil is the first listed.
NCT00307736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00307736 about?
NCT00307736 is a clinical study titled "Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer". The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating(Phase II ...
What is the current status of trial NCT00307736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00307736?
The interventions under investigation include: 5-fluorouracil (DRUG), bevacizumab (DRUG), erlotinib (DRUG), External beam radiation therapy (EBRT) (PROCEDURE).
Who is sponsoring clinical trial NCT00307736?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.